HRP20161530T1 - 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori - Google Patents

2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori Download PDF

Info

Publication number
HRP20161530T1
HRP20161530T1 HRP20161530TT HRP20161530T HRP20161530T1 HR P20161530 T1 HRP20161530 T1 HR P20161530T1 HR P20161530T T HRP20161530T T HR P20161530TT HR P20161530 T HRP20161530 T HR P20161530T HR P20161530 T1 HRP20161530 T1 HR P20161530T1
Authority
HR
Croatia
Prior art keywords
pyrrolo
pyridin
methanone
benzo
methyl
Prior art date
Application number
HRP20161530TT
Other languages
English (en)
Croatian (hr)
Inventor
Stephen John Atkinson
Michael David Barker
Matthew Campbell
Hawa Diallo
Clement Douault
Neil Stuart Garton
John Liddle
Robert John Sheppard
Ann Louis Walker
Christopher WELLAWAY
David Matthew Wilson
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HRP20161530T1 publication Critical patent/HRP20161530T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20161530TT 2012-07-26 2012-07-26 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori HRP20161530T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12740581.9A EP2877467B1 (en) 2012-07-26 2012-07-26 2-(azaindol-2-yl)benzimidazoles as pad4 inhibitors
PCT/EP2012/064649 WO2014015905A1 (en) 2012-07-26 2012-07-26 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors

Publications (1)

Publication Number Publication Date
HRP20161530T1 true HRP20161530T1 (hr) 2017-02-10

Family

ID=49996626

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161530TT HRP20161530T1 (hr) 2012-07-26 2012-07-26 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori

Country Status (22)

Country Link
US (4) US9127003B2 (https=)
EP (1) EP2877467B1 (https=)
JP (1) JP6063567B2 (https=)
KR (1) KR101916443B1 (https=)
CN (1) CN104470919B (https=)
AU (1) AU2012386257B2 (https=)
BR (1) BR112015001545B1 (https=)
CA (1) CA2879341C (https=)
CY (1) CY1118524T1 (https=)
DK (1) DK2877467T3 (https=)
ES (1) ES2609126T3 (https=)
HR (1) HRP20161530T1 (https=)
HU (1) HUE033294T2 (https=)
IN (1) IN2014KN02935A (https=)
LT (1) LT2877467T (https=)
PL (1) PL2877467T3 (https=)
PT (1) PT2877467T (https=)
RS (1) RS55684B1 (https=)
RU (1) RU2611010C2 (https=)
SI (1) SI2877467T1 (https=)
SM (2) SMT201700052T1 (https=)
WO (1) WO2014015905A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10407407B2 (en) * 2015-05-21 2019-09-10 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as PAD4 inhibitors
AR107030A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
JP6926126B2 (ja) * 2016-02-23 2021-08-25 パドロック・セラピューティクス・インコーポレイテッドPadlock Therapeutics, Inc. Pad4のヘテロアリール阻害剤
CN107188867A (zh) * 2016-03-14 2017-09-22 中国科学院天津工业生物技术研究所 精氨酸脱亚氨酶4的抑制剂
KR102398941B1 (ko) * 2016-07-27 2022-05-17 패들락 테라퓨틱스, 인코포레이티드 Pad4의 공유결합성 억제제
JP7118951B2 (ja) * 2016-09-12 2022-08-16 パドロック・セラピューティクス・インコーポレイテッド Pad4のヘテロアリール阻害剤
US11208386B2 (en) 2016-12-02 2021-12-28 University Of Massachusetts Inhibitors of protein arginine deiminases (PADs) and methods of preparation and use thereof
CN108689946B (zh) * 2017-04-12 2022-10-18 中国科学院上海药物研究所 2-取代硫基乙酰胺类化合物及其制备方法和应用
MX2020003242A (es) * 2017-09-22 2020-09-18 Jubilant Epipad LLC Compuestos heterociclicos como inhibidores de pad.
AU2018352142B2 (en) * 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
EP3760628A4 (en) * 2018-02-26 2021-10-13 Nanjing Transthera Biosciences Co., Ltd. PEPTIDYLARGININE DEIMINASE INHIBITOR AND ITS USES
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
CN112789087B (zh) * 2018-08-08 2024-08-13 百时美施贵宝公司 Pad酶的苯并咪唑抑制剂
AU2019319835A1 (en) 2018-08-08 2021-03-25 Bristol-Myers Squibb Company Indole and azaindole inhibitors of PAD enzymes
EP3833671B1 (en) 2018-08-08 2022-08-24 Bristol-Myers Squibb Company Substituted thienopyrroles as pad4 inhibitors
WO2020033488A1 (en) * 2018-08-08 2020-02-13 Bristol-Myers Squibb Company Substituted benzimidazoles as pad4 inhibitors
CN109369513B (zh) * 2018-11-20 2020-08-25 都创(上海)医药科技有限公司 一种fbdd常用分子片段的制备方法
WO2020132045A1 (en) 2018-12-19 2020-06-25 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
EP3994128A4 (en) * 2019-07-03 2022-12-07 University of Massachusetts INHIBITORS OF PROTEIN ARGININE DEIMINASE 1, AND PROCESSES FOR THEIR PREPARATION AND USE
TW202115083A (zh) * 2019-09-27 2021-04-16 大陸商南京藥捷安康生物科技有限公司 肽醯精胺酸脫亞胺酶抑制劑及其用途
EP4100405A1 (en) * 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Macrocyclic pad4 inhibitors useful as immunosuppressant
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
CN111265526B (zh) * 2020-04-09 2021-03-19 黑龙江中医药大学 一种治疗胃癌的药物及其制备方法
EP4143189A1 (en) * 2020-04-30 2023-03-08 Gilead Sciences, Inc. Macrocyclic inhibitors of peptidylarginine deiminases
JP2023541601A (ja) 2020-09-10 2023-10-03 プレシリックス・ナームローゼ・ベンノートシヤープ Fapに対する抗体フラグメント
AU2021343770A1 (en) 2020-09-18 2023-05-18 Carna Biosciences, Inc. Amine derivative
TW202241884A (zh) 2020-12-22 2022-11-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
WO2022140428A2 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
CN118679162A (zh) 2021-11-15 2024-09-20 锐格药业公司 Pad4抑制剂及其用途
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
CA3251753A1 (en) 2022-05-02 2023-11-09 Precirix N.V. PRE-TARGETTING
US20250346592A1 (en) * 2022-05-26 2025-11-13 Celgene Corporation Heterocyclic pad4 inhibitors
WO2024109945A1 (en) * 2022-11-24 2024-05-30 Helios Huaming Biopharma Co., Ltd. Selenium containing heterocycle compounds and use thereof
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
AP791A (en) 1995-04-14 1999-12-17 Glaxo Wellcome Inc Metered dose inhaler for albuterol.
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
CA2344262A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft 4-aminopyrrolopyrimidines as kinase inhibitors
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
AU778042B2 (en) * 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
OA12514A (en) 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
ES2388434T3 (es) 2003-11-03 2012-10-15 Glaxo Group Limited Dispositivo de administración de fluido
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7429611B2 (en) * 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
EP2205085A1 (en) 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
EP2300460A1 (en) 2008-05-28 2011-03-30 Wyeth LLC 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
RU2011106786A (ru) * 2008-07-23 2012-08-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы пиразолопиридинкиназы
WO2010115736A2 (en) * 2009-04-02 2010-10-14 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
WO2010118208A1 (en) 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer

Also Published As

Publication number Publication date
PT2877467T (pt) 2017-01-02
CA2879341C (en) 2019-06-11
WO2014015905A1 (en) 2014-01-30
CN104470919B (zh) 2016-07-06
RU2014152456A (ru) 2016-09-20
JP6063567B2 (ja) 2017-01-18
RU2611010C2 (ru) 2017-02-17
JP2015522628A (ja) 2015-08-06
US20160009716A1 (en) 2016-01-14
BR112015001545A2 (pt) 2017-07-04
KR101916443B1 (ko) 2018-11-08
HUE033294T2 (en) 2017-11-28
US20180161316A1 (en) 2018-06-14
US9833449B2 (en) 2017-12-05
KR20150038438A (ko) 2015-04-08
BR112015001545B1 (pt) 2022-07-05
SMT201700052B (it) 2017-03-08
CA2879341A1 (en) 2014-01-30
IN2014KN02935A (https=) 2015-05-08
US9518054B2 (en) 2016-12-13
EP2877467A1 (en) 2015-06-03
EP2877467B1 (en) 2016-11-02
CN104470919A (zh) 2015-03-25
SMT201700052T1 (it) 2017-03-08
ES2609126T3 (es) 2017-04-18
US9127003B2 (en) 2015-09-08
DK2877467T3 (en) 2017-02-13
US20150175600A1 (en) 2015-06-25
CY1118524T1 (el) 2017-07-12
US20170119750A1 (en) 2017-05-04
SI2877467T1 (sl) 2017-02-28
LT2877467T (lt) 2017-01-10
AU2012386257A1 (en) 2015-03-12
AU2012386257B2 (en) 2016-09-08
US10039755B2 (en) 2018-08-07
RS55684B1 (sr) 2017-07-31
PL2877467T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
HRP20161530T1 (hr) 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori
FIC20200051I1 (fi) Entrektinibi tai sen tautomeerit tai farmaseuttisesti hyväksyttävät suolat
MX2010005824A (es) Derivados de aminotiazol.
EP2509602A4 (en) Pyrazolopyrimidine and Corresponding Heterocycles as CK2 Inhibitors
WO2008046758A3 (en) Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
NZ600840A (en) Indole compound and pharmaceutical use thereof
IL216741A0 (en) 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
IL212250A0 (en) Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition
EP2438079A4 (en) NUCLEIC ACID DELIVERY COMPOSITIONS AND METHOD OF USE THEREOF
EP2549863A4 (en) COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORTATION
IN2012DN03337A (https=)
FR2951885B1 (fr) Dispositif d'amplification multi-ports compense en presence de trafic
ZA201200585B (en) "indole derivative and pharmaceutically acceptable salt thereof"
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
EP2137091B1 (fr) Dispositif d'orientation de preformes
FR2940116B1 (fr) Formulation pour l'administration d'hypolipemiant par voie trans-muqueuse buccale
ZA200902575B (en) Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof
TW200740764A (en) Pyrazolone derivatives
MX2011011716A (es) Derivados de isoquinolina novedosos.
IT1401912B1 (it) Sistema per verificare l'autenticita' di articoli
FR2940267B1 (fr) Procede de preparation d'un oxalate d'actinide(s) et de preparation d'un compose d'actinide(s)
FR2940120B1 (fr) Formulation pour l'administration par voie trans-muqueuse de setrons
IL195426A0 (en) Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor
IT1397285B1 (it) Glicosaminoglicani solforati, includenti l'eparina, l'eparina a basso peso molecolare e i loro derivati, per l'impiego nel trattamento terapeutico di anemie e per l'inibizione dell'espressione di epcidina.
EP2271469A4 (en) FORM AND FORMNEST FOR PREPARATION